KAT5 Inhibitor NU9056 Suppresses Anaplastic Thyroid Carcinoma Progression through c-Myc/miR-202 Pathway

Figure 6

NU9056 inhibits miR-202-5p expression in human ATC cells. 8505C cells transiently transfected with either control or KAT5 plasmid, and microRNA sequencing was conducted (A-D). Cal-62 (E) cells were left untreated or treated with NU9056 (5–20uM), and the expression of miR-202-5p was detected by qRT-PCR (E). The SPF mice were injected with Cal-62 cells at the right flanks and were divided into control or NU9056 group. After 21 days, mice were killed and the expression of miR-202-5p of the tumor was detected by qRT-PCR (F). Cal-62 cells were transiently transfected with either control or miR-202-5p antagomir, and the knockdown effect was detected by RT-PCR (G). Then, cells were left untreated or treated with NU9056, and cell viability (H) and invasion ability (I) were tested by the appropriate assay. Cal-62 cells were transiently transfected with either control or miR-202-5p mimic, and the transfection effect was detected by RT-PCR (J). Then, cells were treated with NU9056, and cell viability (K) was tested by the appropriate assay. vs. “Ctrl” group, vs. “Ctrl” group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)